CHAPTERS
- 0:00 – 2:11
Peptides targeted by regulators: what’s actually happening and why it matters
Joe and Brigham frame the current “war on peptides” as a regulatory move that effectively destroys access without an outright ban. They set up the central claim: the action is less about safety and more about protecting profit and market control.
- 2:11 – 4:31
A history lesson on pharma misconduct and the “medical‑industrial complex”
Brigham argues that to understand peptide policy, you have to understand the historical pattern of private industry influencing government. He cites notorious examples and ties them to Eisenhower’s warning about the medical-industrial complex.
- 4:31 – 7:14
From HIV contamination to opioids: recurring incentives and repeat failures
The conversation moves through examples meant to show how companies and regulators behave when profit conflicts with safety. Brigham connects these stories to why he believes peptide access is being squeezed now.
- 7:14 – 8:44
How peptides get ‘killed’ without a ban: dangerous lists, patents, and market signals
Brigham explains the mechanism: labeling compounds as “dangerous” chills physician prescribing and collapses legitimate supply. He contrasts targeted peptides with patented peptide drugs that remain widely available.
- 8:44 – 17:33
PBMs, insurers, and DOJ pressure: how enforcement shapes medical behavior
Brigham claims insurers and PBMs can effectively weaponize enforcement by feeding narratives and data to prosecutors. He uses the out-of-network billing dynamic to illustrate how normal business realities can be reframed as fraud.
- 17:33 – 20:56
Compounding pharmacy safety vs Big Pharma manufacturing: who gets scrutinized?
Brigham outlines sterility, sourcing, third-party testing, and documentation practices he says reputable compounders follow. He contrasts that with claims of infrequent inspection and offshore manufacturing vulnerabilities in large pharma supply chains.
- 20:56 – 25:00
GLP‑1s, shortages, and lawsuits: compounding as a workaround—and a target
They discuss GLP‑1 shortages and how compounding pharmacies produce alternative doses during backorders. Brigham argues pharma then sues compounders while running PR campaigns that portray compounding as unsafe.
- 25:00 – 39:10
Media incentives and the revolving door: pandemic fallout and trust collapse
Joe and Brigham connect pharma influence to advertising-driven media coverage and public distrust after COVID-era messaging. They also discuss regulators moving into industry roles as evidence of revolving-door incentives.
- 39:10 – 47:44
Devices, 510(k), and underreported adverse events: why ‘approved’ doesn’t mean safe
Brigham pivots to medical devices, arguing the 510(k) pathway allows widespread use without human safety trials. He shares rep-era anecdotes about sterile processing, contamination risk, and underreporting of adverse events.
- 47:44 – 48:56
Why he built Ways2Well & Revive: escaping insurance and building cash‑pay care
Brigham explains his entrepreneurial arc: opioid loss in his family, building alternatives, and being crushed by insurance reimbursement changes. He argues cash-pay models enable root-cause care, testing, and flexibility that insurance discourages.
- 48:56 – 1:04:03
Testosterone, medical dogma, and the PBM-driven formulary machine
They use testosterone therapy as an example of how long debunked ideas can persist in mainstream medicine. Brigham then expands into PBMs, rebates, and tiering systems that he claims prioritize profitability over outcomes.
- 1:04:03 – 1:42:12
The future: AI/LLMs for personalized medicine—and the privacy/insurance risk
Brigham lays out a vision where large language models help scale proactive, data-driven care by integrating EMRs, imaging, labs, and wearables. They also discuss bias, closed vs open data systems, and the danger of insurers using AI to deny care.
- 1:42:12 – 1:50:55
Brain mapping, magnets (MeRT), and psychedelics research for performance and mental health
They explore EEG-based diagnostics and magnet-based neuro-optimization approaches, including potential applications in high-performance settings. Brigham also mentions collaborations around psychedelic microdosing research to quantify cognitive effects.
- 1:50:55 – 2:04:00
Stem cells explained: signaling vs differentiation, regulation limits, and athlete recoveries
Returning from a break, they go deep on what’s legally allowed in the U.S. and what people misunderstand about mesenchymal signaling cells. Brigham emphasizes mechanism-of-action, clinical expectations, and highlights athlete recovery stories including Aaron Rodgers.
- 2:04:00 – 2:14:34
OA knees, cartilage questions, and closing message: optimize healing and build hope
They discuss osteoarthritis evidence, what current studies suggest about cartilage loss, and where regenerative approaches may head next. The episode closes with a broad critique of profit-driven medicine, a call for proactive care, and Brigham’s hiring pitch.
